STUDY CASE

Your one stop point for market access, prelaunch and launch activities in Europe.

Client need and context:

Our client was a European biotech, launching lifesaving drug in Europe in ultra-rare disease. The product concerned about twenty patients in France. It receives a European marketing authorization for ultra-orphan drug.

Our client was seeking support in securing marketing and commercial operation, securing supervision of local regulatory and market access, supporting medical activities, supporting logistics and regulatory, supporting cash collection and participating in global strategy and tactic for 6 countries in Europe and partnership in Scandinavia.

BlueDil approach:

In the first place, BlueDil called on its European network and choose 3 projects managers in United Kingdom, Germany and Italy. Each consultant presented their local specificity in market access.

They were managed from France, to offer a single-entry point to our client.

We then proceed to identify and select a partner in Scandinavia.

With its expertise, BlueDil provided a full local support and controlled expenses, according to client’s need.

Achievements:

Since the beginning of this mission in 2014, BlueDil has handled various task for our client, including:

  • KOL mapping
  • Participation to local and international congresses
  • Organisation and administration of advisory board
  • One single entry point for our client to gather all information

BlueDil’s disease area strategy was fully endorsed and implemented, resulting with a success with obtaining target price and full unconditional reimbursement. All relevant physicians were engaged.

Despite three competitors in the rare condition, our client was able to reach 100% market penetration. BlueDil’s territory represents about 50% of the world wide sales.

Benefits for you:

  • End-to-end supervision and support in the countries
  • Commercial success: the drug was able to reach 100% market penetration
  • Immediate action: our team was on the field to start the mission right after the contract’s signature.
  • Light investment Valuable input to the client strategy
  • Low structure: one consultant by country.